ClinicalTrials.gg
TerminatedNCT02070978Updated Mar 21, 2019Results posted

Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Participant Who Participated in ADDRESS II)

A Phase 2 interventional study of Atacicept 75 mg and Atacicept 150 mg in Lupus Erythematosus, Systemic, sponsored by EMD Serono. Terminated at 84 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-21.

Sponsored by EMD Serono (part of Merck KGaA, Darmstadt, Germany) · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
The study was terminated early due to shortage of drug supply.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
253
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 12 studies in Lupus Erythematosus, Systemic by Merck KGaA, Darmstadt, Germany — 3 open to participants now, 4 under way, 3 of them phase 3. Lupus Erythematosus, Systemic · Merck KGaA, Darmstadt, Germany.

Enrollment
7th of 12
253 · median 280
Started
2014
the only one that year
Phase 2
6 of 12
none open now
Registered
4th of 12
by date

Among the 12 studies in Lupus Erythematosus, Systemic by Merck KGaA, Darmstadt, Germany, this one is the 7th largest by enrollment, is the only one that started in 2014, is one of 6 in phase 2, and was the 4th registered.

Lupus Erythematosus, Systemic

1,211 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

3 of the 12 studies in Lupus Erythematosus, Systemic by Merck KGaA, Darmstadt, Germany are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 94 (33%) set no upper age limit and 160 (56%) stop at 75 or younger; 54 take children under 18; 32 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Lupus Erythematosus, Systemic by Merck KGaA, Darmstadt, Germany, or all of them as a file.
02

Study summary

This is a multicenter, double-blind, Phase 2b, long-term extension (LTE) to the ADDRESS II core trial (EMR 700461-023) (NCT01972568), to evaluate long-term safety and tolerability of atacicept in participants with systemic lupus erythematosus (SLE). Participants who completed the 24-week core study ADDRESS II core study (NCT01972568) and thus not met any of the discontinuation criteria were invited to enter this long-term extension (LTE) study NCT02070978.

03

Conditions studied

  • Lupus Erythematosus, Systemic

Keywords

  • Lupus Erythematosus, Systemic
  • Atacicept 75 and 150 mg
  • LTE
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who had completed the 24-week treatment period of study EMR-700461-023 (ADDRESS II core trial)
  • Women of who had a negative pregnancy test
  • Other protocol defined inclusion criteria were applied

Exclusion criteria

Exclusion Criteria:

  • Active neurological symptoms of SLE that were deemed severe or progressive
  • Diagnosis of any demyelinating disease, such as, but not restricted to, multiple sclerosis (MS) or optic neuritis
  • Pregnancy
  • Active viral, bacterial, or fungal infection, or any major episode of infection that in the investigator's opinion makes the participants unsuitable to continued participation in the study
  • Other protocol defined exclusion criteria were applied
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
253 participants (actual)

Study arms

  • Experimental
    Atacicept 75 mg

    Drug: Atacicept 75 mg

  • Experimental
    Atacicept 150 mg

    Drug: Atacicept 150 mg

  • Experimental
    Placebo/Atacicept 150 mg

    Drug: Atacicept 150 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With at Least One Serious Adverse Event (SAE) During the Treatment Period

    An Adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease associated with the use of study drug, whether or not considered related to the study drug or worsening of pre-existing medical condition, whether or not related to study drug. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. An AE was considered as 'treatment emergent' if it occurred after the first drug administration of each period or if it was present prior to drug administration but exacerbated after the drug administration. Treatment- Emergent adverse events (TEAEs) during the treatment period exclude those ongoing at the time of study entry into 024 LTE Day 1 and exclude the safety follow-up period.

    Time frame: Baseline (LTE Day 1) up to maximum treatment duration of 143.7 weeks

  2. Number of Participants Who Prematurely Discontinued the Treatment Due to Adverse Event (AE)

    An Adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease associated with the use of study drug, whether or not considered related to the study drug or worsening of pre-existing medical condition, whether or not related to study drug. TEAEs were defined as events with an onset date on or after the date of first dose of study treatment in the core study and ongoing at the 024 LTE study entry, occurring during the 024 LTE study and the Safety follow-up Period.

    Time frame: Baseline (Day 1 of Core study) up to maximum duration of 167.7 weeks

Secondary outcomes

  1. Change From Baseline in Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index Organ Damage Scores

    SLICC/ACR score or damage index evaluates cumulative damage in Systemic Lupus Erythematosus (SLE). These changes may or may not be related to SLE. Most items are scored only if they have been present for at least 6 months. Scores range from 0 to 47 points, with higher scores indicating greater cumulative damage. Baseline was defined as Day 1 of Core study.

    Time frame: Baseline: Day 1 (Core Study), Day 1 (LTE Study), Week 24, Week 48, Week 72 and Week 96

  2. Change From Baseline in Disease Activity as Measured by British Isles Lupus Assessment Group (BILAG) 2004 Score

    BILAG Disease Activity Index evaluates systemic lupus erythematosus (SLE) activity in 8 organ system domains: General, mucocutaneous, neurological, musculoskeletal, cardiorespiratory, vasculitis, renal, and hematologic using a separate alphabetic score (A to E) assigned to each organ system defined as follows. BILAG A: Severe disease activity; BILAG B: moderate disease activity; BILAG C: mild disease; BILAG D: system previously affected but now inactive; BILAG E: system never involved. BILAG evaluated by scoring each of a list of signs and symptoms as: improving (1); same (2); worse (3); new (4); not present (0); not done (ND). The total BILAG score is the sum of the scores of the 8 domains where A=9, B=3, C=1, D=0, and E=0. The total score ranges from 0 to 72 with a higher score indicating greater lupus activity.

    Time frame: Baseline: Core study Screening, LTE Day 1, Week 24, Week 48, Week 72 and Week 96

  3. Change From Baseline in Disease Activity as Measured by Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) Score

    SLEDAI-2K is an activity index that measures disease activity and records feature of active lupus as present or not present. SLEDAI-2K uses a weighted checklist to assign a numerical score based on the presence or absence of 24 symptoms. Each symptom present is assigned between 1 and 8 points based on its usual clinical importance, yielding a total score that ranges from 0 points (no symptoms) to 105 points (presence of all defined symptoms). Baseline was defined as core study screening visit.

    Time frame: Baseline: Screening Visit (Core Study); LTE Day 1, Week 24, Week 48, Week 72 and Week 96

  4. Change From Baseline in Disease Activity as Measured by SLEDAI-2K Responder Index-50 (SRI-50) Score

    SRI-50 index was derived from SLEDAI-2K and could capture 50% or better improvement in each descriptor between any 2 visits in systemic lupus erythematosus (SLE) participants when there was incomplete resolution. The new assigned scores for the descriptors of SRI-50 were derived by dividing the score of each SLEDAI-2K descriptor by 2. SLEDAI-2K was an activity index that measured disease activity and records feature of active lupus as present or not present. SLEDAI-2K used a weighted checklist to assign a numerical score based on the presence or absence of 24 symptoms. Each symptom present was assigned between 1 and 8 points based on its usual clinical importance, yielding a total score that ranged from 0 points (no symptoms) to 105 points (presence of all defined symptoms).

    Time frame: Baseline: Screening Visit (Core Study); LTE Day 1, Week 24, Week 48, Week 72 and Week 96

  5. Change From Baseline in Disease Activity as Measured by Physician's Global Assessment (PGA) Score

    The PGA was used to quantify disease activity and was measured using an anchored visual analog scale (VAS). The participant's current disease activity assessed by investigator in the score range of 0 to 3. Where 0=none; 1=mild; 2=moderate; 3=severe. The assessment made relative not to the participant's most severe state, but the most severe state of systemic lupus erythematosus (SLE) per the investigator's assessment. Baseline was defined as core study screening visit.

    Time frame: Baseline: Screening Visit (Core Study); LTE Day1, Week 24, Week 48, Week 72 and Week 96

  6. Number of Participants Who Achieved SLE Responder Index (SRI-4) Response (a Disease Activity Composite Index)

    SRI-4 response was defined as greater than or equal to 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score, no new British Isles Lupus Assessment Group (BILAG) A and no more than 1 new BILAG B domain score and no worsening (less than 10 percent increase) from baseline Physician's Global Assessment of Disease Activity (PGA). SLEDAI-2K is an activity index that measures disease activity and records feature of active lupus as present or not present. SLEDAI-2K uses a weighted checklist to assign a numerical score based on the presence or absence of 24 symptoms. Each symptom present is assigned between 1 and 8 points based on its usual clinical importance, yielding a total score that ranges from 0 points (no symptoms) to 105 points (presence of all defined symptoms).

    Time frame: Baseline: Core study Screening; LTE Day 1, Week 24, Week 48, Week 72 and Week 96

  7. Number of Participants Who Achieved BILAG-based Combined Lupus Assessment (BICLA) Response (a Disease Activity Composite Index)

    The BICLA response was defined as BILAG-2004 improvement (all screening visit BILAG A improving to B/C/D, all screening visit BILAG B to C/D, and less than or equal to (\<=1) new BILAG B and no new BILAG A); no deterioration in SLEDAI total score; PGA increase by less than (\<) 0 percentage (%) (defined as less then (\<)0.3 point increase for the statistical analyses) and no non-permitted medication/treatment. Baseline was defined as core study screening visit.

    Time frame: Baseline: Core study Screening; LTE Day 1, Week 24, Week 48, Week 72 and Week 96

  8. Percent Change From Baseline in Prednisone-equivalent Corticosteroid Dose

    Time frame: Baseline: Screening Visit (Core Study); LTE Day 1, Week 24, Week 48, Week 72 and Week 96

  9. Change From Baseline in the Short-Form (SF-36) Health Survey Physical Component Score and Mental Component Score

    The 36-Item Short-Form Health Survey (SF-36) is a standardized survey evaluating 8 aspects of functional health and well-being. These eight subscales were summarized as relating to either physical health or mental health. Physical component summary (PCS) is based primarily on physical functioning, role-physical, bodily pain, and general health scales and mental component summary (MCS) encompasses vitality, social functioning, role-emotional, and mental health scales. Score from mental health, role emotional, social functioning, and vitality domains were averaged to calculate MCS. Total score range for MCS was 0-100 (100=highest level of mental functioning). Score from physical function, role physical, bodily pain, and general health domains were averaged to calculate PCS. Total score range for PCS was 0-100 (100=highest level of physical functioning).

    Time frame: Baseline (Core Study Day 1); LTE Day 1, Week 24, Week 48, Week 72 and Week 96

  10. Change From Baseline in Lupus Quality of Life (LupusQoL) Questionnaire Score

    The LupusQoL was a lupus-specific health related QoL (HRQoL) questionnaire consisting of 34 items grouped in 8 domains: physical health, pain, planning, intimate relationships, burden to others, emotional health, body image, and fatigue. Participants indicate their responses on a 5-point Likert response format, where 4 = never, 3 = occasionally, 2 = a good bit of the time, 1 = most of the time, and 0 = all of the time. Summary scores can be calculated for all 8 domains. A LupusQoL score for each domain was reported on a 0 to 100 scale, with greater values indicating better HRQoL. Baseline was defined as Day 1 of core study.

    Time frame: Baseline (Core Study Day 1); LTE Day 1, Week 24, Week 48, Week 72, and Week 96

  11. Number of Participants With Patient Global Impression of Change (PGIC)

    The PGIC is self-rated scale that asks the participant to describe the change in activity limitations, symptoms, emotions, and overall Quality of life (QoL) related to the participant's painful condition on the following scale: 1 (very much improved), 2 (much improved), 3 (minimally improved), 4 (no change), 5 (minimally worse), 6 (much worse) and 7 (very much worse). Number of participants in the PGIC categories of very much improved (1) and much improved (2) are reported.

    Time frame: Baseline (Core Study Day 1); LTE Day 1, Week 24, Week 48, Week 72 and Week 96

  12. Change From Baseline in EuroQoL 5 Dimension Instrument (EQ-5D) Score

    EQ-5D questionnaire comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression measured on 3 levels; 1=no problem, 2=moderate problems, 3=extreme problems. This part, called the EQ-5D descriptive system, provides a 5-dimensional description of health status. 5 dimensional 3-level system was converted into single index utility score. Possible values for single index utility score ranged from -0.594 (severe problems in all dimensions) to 1.0 (no problem in all dimensions) on scale where 1 represented best possible health state. Baseline was defined as Day 1 of Core study.

    Time frame: Baseline: Day 1 (Core Study), LTE Day 1, Week 24, Week 48, Week 72 and Week 96

  13. Change From Baseline in EQ-5D Visual Analogue Scale (VAS) Scores

    EQ-5D is a participant rated questionnaire to assess health-related QoL in terms of a single index value. The VAS component rates current health state on a scale from 0 millimeters (mm) (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state. Baseline defined as Day 1 of core study.

    Time frame: Baseline: Day 1 (Core Study), LTE Day 1, Week 24, Week 48, Week 72 and Week 96

  14. Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score

    The FACIT-Fatigue score was calculated according to a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function. It uses a 5-point Likert-type scale (0 = not at all; 1 = a little bit; 2 = somewhat; 3 = quite a bit; 4 = very much). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse possible score) to 52 (best score). A higher score reflected an improvement in the participant's health status.

    Time frame: Baseline: Day 1 (Core study); LTE Day 1, Week 24, Week 48, Week 72 and Week 96

  15. Number of Participants With at Least One Adverse Event

    An Adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease associated with the use of study drug, whether or not considered related to the study drug or worsening of pre-existing medical condition, whether or not related to study drug. Treatment-Emergent adverse events (TEAEs) are defined as events with an onset date on or after the date of first dose of study treatment in the core study and ongoing at LTE study entry, or occurring during LTE study.

    Time frame: Baseline (Day 1 of Core study) up to maximum duration of 167.7 weeks

  16. Number of Participants With Columbia-Suicide Severity Rating Scale (C-SSRS) Score

    The C-SSRS assesses the suicidal behavior and suicidal ideation in participants. Occurrence of suicidal behavior after study entry is defined as having answered "yes" to a least 1 of the 4 suicidal behavior subcategories (actual attempt, interrupted attempt, aborted attempt, and preparatory acts or behavior). Occurrence of suicidal ideation is defined as having answered "yes" to at least 1 of the suicidal ideation sub-categories (1) wish to be dead, (2) nonspecific active suicidal thoughts, (3) active suicidal ideation with any methods (no plan) without intent to act, (4) active suicidal ideation with some intent to act (without specific plan), and (5) active suicidal ideation with specific plan and intent).

    Time frame: LTE Day 1, Week 24, Week 48, Week 72 and Week 98

07

Results

Posted Mar 21, 2019
Limitations and caveats
The study was terminated early due to shortage of drug supply and there were many fewer number of participants remaining in each dosage group after Week 72 preluding meaningful inferences.

Participant flow

Participants who completed 24-week of the ADDRESS II core study (NCT01972568) and didn't meet any discontinuation criteria were enrolled in this long-term extension (LTE) study NCT02070978. The study was conducted at 81 sites in 17 countries in Asia, Europe, North America, Central America, and South America.

Participant flow — Overall Study
MilestonePlacebo/Atacicept 150 mgAtacicept 75 mgAtacicept 150 mg
Started838288
Completed362935
Not completed475353
Withdrew: Adverse event620
Withdrew: Lost to follow-up134
Withdrew: Withdrawal by subject353
Withdrew: Protocol violation103
Withdrew: Lack of efficacy010
Withdrew: Death002
Withdrew: Un-specified322
Withdrew: Terminated by sponsor334039

Outcome measures

PrimaryNumber of Participants With at Least One Serious Adverse Event (SAE) During the Treatment Period

An Adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease associated with the use of study drug, whether or not considered related to the study drug or worsening of pre-existing medical condition, whether or not related to study drug. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. An AE was considered as 'treatment emergent' if it occurred after the first drug administration of each period or if it was present prior to drug administration but exacerbated after the drug administration. Treatment- Emergent adverse events (TEAEs) during the treatment period exclude those ongoing at the time of study entry into 024 LTE Day 1 and exclude the safety follow-up period.

Time frame:
Baseline (LTE Day 1) up to maximum treatment duration of 143.7 weeks
Reported as:
Count of participants · Participants
Number of Participants With at Least One Serious Adverse Event (SAE) During the Treatment Period
ParticipantsPlacebo/Atacicept 150 mgAtacicept 75 mgAtacicept 150 mg
Number of Participants With at Least One Serious Adverse Event (SAE) During the Treatment Period13109
PrimaryNumber of Participants Who Prematurely Discontinued the Treatment Due to Adverse Event (AE)

An Adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease associated with the use of study drug, whether or not considered related to the study drug or worsening of pre-existing medical condition, whether or not related to study drug. TEAEs were defined as events with an onset date on or after the date of first dose of study treatment in the core study and ongoing at the 024 LTE study entry, occurring during the 024 LTE study and the Safety follow-up Period.

Time frame:
Baseline (Day 1 of Core study) up to maximum duration of 167.7 weeks
Reported as:
Count of participants · Participants
Number of Participants Who Prematurely Discontinued the Treatment Due to Adverse Event (AE)
ParticipantsPlacebo/Atacicept 150 mgAtacicept 75 mgAtacicept 150 mg
Number of Participants Who Prematurely Discontinued the Treatment Due to Adverse Event (AE)945
SecondaryChange From Baseline in Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index Organ Damage Scores

SLICC/ACR score or damage index evaluates cumulative damage in Systemic Lupus Erythematosus (SLE). These changes may or may not be related to SLE. Most items are scored only if they have been present for at least 6 months. Scores range from 0 to 47 points, with higher scores indicating greater cumulative damage. Baseline was defined as Day 1 of Core study.

Time frame:
Baseline: Day 1 (Core Study), Day 1 (LTE Study), Week 24, Week 48, Week 72 and Week 96
Reported as:
Mean · Units on a scale
Change From Baseline in Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index Organ Damage Scores
Units on a scalePlacebo/Atacicept 150 mgAtacicept 75 mgAtacicept 150 mg
Baseline; Day 1 (Core Study)1 ± 1.01 ± 1.20 ± 0.8
Change at LTE Day 10 ± 0.00 ± 0.10 ± 0.0
Change at LTE Week 240 ± 0.10 ± 0.10 ± 0.2
Change at LTE Week 480 ± 0.20 ± 0.20 ± 0.3
Change at LTE Week 720 ± 0.30 ± 0.30 ± 0.2
Change at LTE Week 960 ± 0.30 ± 0.30 ± 0.0
SecondaryChange From Baseline in Disease Activity as Measured by British Isles Lupus Assessment Group (BILAG) 2004 Score

BILAG Disease Activity Index evaluates systemic lupus erythematosus (SLE) activity in 8 organ system domains: General, mucocutaneous, neurological, musculoskeletal, cardiorespiratory, vasculitis, renal, and hematologic using a separate alphabetic score (A to E) assigned to each organ system defined as follows. BILAG A: Severe disease activity; BILAG B: moderate disease activity; BILAG C: mild disease; BILAG D: system previously affected but now inactive; BILAG E: system never involved. BILAG evaluated by scoring each of a list of signs and symptoms as: improving (1); same (2); worse (3); new (4); not present (0); not done (ND). The total BILAG score is the sum of the scores of the 8 domains where A=9, B=3, C=1, D=0, and E=0. The total score ranges from 0 to 72 with a higher score indicating greater lupus activity.

Time frame:
Baseline: Core study Screening, LTE Day 1, Week 24, Week 48, Week 72 and Week 96
Reported as:
Mean · Units on a scale
Change From Baseline in Disease Activity as Measured by British Isles Lupus Assessment Group (BILAG) 2004 Score
Units on a scalePlacebo/Atacicept 150 mgAtacicept 75 mgAtacicept 150 mg
Baseline: Core study Screening15 ± 7.114 ± 7.216 ± 6.1
Change at LTE Day 1-8 ± 6.9-9 ± 7.2-10 ± 6.8
Change at LTE Week 24-8 ± 8.3-10 ± 7.5-12 ± 7.2
Change at LTE Week 48-9 ± 7.7-8 ± 7.5-11 ± 7.4
Change at LTE Week 72-9 ± 7.9-10 ± 6.2-11 ± 8.2
Change at LTE Week 96-14 ± 12.9-8 ± 6.3-12 ± 6.8
SecondaryChange From Baseline in Disease Activity as Measured by Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) Score

SLEDAI-2K is an activity index that measures disease activity and records feature of active lupus as present or not present. SLEDAI-2K uses a weighted checklist to assign a numerical score based on the presence or absence of 24 symptoms. Each symptom present is assigned between 1 and 8 points based on its usual clinical importance, yielding a total score that ranges from 0 points (no symptoms) to 105 points (presence of all defined symptoms). Baseline was defined as core study screening visit.

Time frame:
Baseline: Screening Visit (Core Study); LTE Day 1, Week 24, Week 48, Week 72 and Week 96
Reported as:
Mean · Units on a scale
Change From Baseline in Disease Activity as Measured by Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) Score
Units on a scalePlacebo/Atacicept 150 mgAtacicept 75 mgAtacicept 150 mg
Baseline: Screening Visit (Core Study)10 ± 2.910 ± 3.410 ± 3.0
Change at LTE Day 1-4 ± 4.1-5 ± 4.5-5 ± 3.9
Change at LTE Week 24-5 ± 4.3-6 ± 4.1-6 ± 3.9
Change at LTE Week 48-6 ± 3.4-6 ± 4.6-7 ± 4.3
Change at LTE Week 72-5 ± 3.8-6 ± 3.7-7 ± 3.9
Change at LTE Week 96-7 ± 5.0-6 ± 4.9-8 ± 2.7
SecondaryChange From Baseline in Disease Activity as Measured by SLEDAI-2K Responder Index-50 (SRI-50) Score

SRI-50 index was derived from SLEDAI-2K and could capture 50% or better improvement in each descriptor between any 2 visits in systemic lupus erythematosus (SLE) participants when there was incomplete resolution. The new assigned scores for the descriptors of SRI-50 were derived by dividing the score of each SLEDAI-2K descriptor by 2. SLEDAI-2K was an activity index that measured disease activity and records feature of active lupus as present or not present. SLEDAI-2K used a weighted checklist to assign a numerical score based on the presence or absence of 24 symptoms. Each symptom present was assigned between 1 and 8 points based on its usual clinical importance, yielding a total score that ranged from 0 points (no symptoms) to 105 points (presence of all defined symptoms).

Time frame:
Baseline: Screening Visit (Core Study); LTE Day 1, Week 24, Week 48, Week 72 and Week 96

No measurements were reported for this outcome.

SecondaryChange From Baseline in Disease Activity as Measured by Physician's Global Assessment (PGA) Score

The PGA was used to quantify disease activity and was measured using an anchored visual analog scale (VAS). The participant's current disease activity assessed by investigator in the score range of 0 to 3. Where 0=none; 1=mild; 2=moderate; 3=severe. The assessment made relative not to the participant's most severe state, but the most severe state of systemic lupus erythematosus (SLE) per the investigator's assessment. Baseline was defined as core study screening visit.

Time frame:
Baseline: Screening Visit (Core Study); LTE Day1, Week 24, Week 48, Week 72 and Week 96
Reported as:
Mean · Units on a scale
Change From Baseline in Disease Activity as Measured by Physician's Global Assessment (PGA) Score
Units on a scalePlacebo/Atacicept 150 mgAtacicept 75 mgAtacicept 150 mg
Baseline: Screening Visit (Core Study)1.56 ± 0.4241.46 ± 0.5091.47 ± 0.460
Change at LTE Day 1-0.76 ± 0.559-0.77 ± 0.559-0.77 ± 0.614
Change at LTE Week 24-0.91 ± 0.620-0.85 ± 0.555-0.94 ± 0.547
Change at LTE Week 48-1.01 ± 0.647-0.86 ± 0.522-0.99 ± 0.557
Change at LTE Week 72-0.90 ± 0.758-0.84 ± 0.503-1.03 ± 0.580
Change at LTE Week 96-1.17 ± 0.518-0.72 ± 0.579-1.21 ± 0.411
SecondaryNumber of Participants Who Achieved SLE Responder Index (SRI-4) Response (a Disease Activity Composite Index)

SRI-4 response was defined as greater than or equal to 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score, no new British Isles Lupus Assessment Group (BILAG) A and no more than 1 new BILAG B domain score and no worsening (less than 10 percent increase) from baseline Physician's Global Assessment of Disease Activity (PGA). SLEDAI-2K is an activity index that measures disease activity and records feature of active lupus as present or not present. SLEDAI-2K uses a weighted checklist to assign a numerical score based on the presence or absence of 24 symptoms. Each symptom present is assigned between 1 and 8 points based on its usual clinical importance, yielding a total score that ranges from 0 points (no symptoms) to 105 points (presence of all defined symptoms).

Time frame:
Baseline: Core study Screening; LTE Day 1, Week 24, Week 48, Week 72 and Week 96
Reported as:
Count of participants · Participants
Number of Participants Who Achieved SLE Responder Index (SRI-4) Response (a Disease Activity Composite Index)
ParticipantsPlacebo/Atacicept 150 mgAtacicept 75 mgAtacicept 150 mg
LTE Day 1425257
LTE Week 24435760
LTE Week 48444651
LTE Week 72212323
LTE Week 966912
SecondaryNumber of Participants Who Achieved BILAG-based Combined Lupus Assessment (BICLA) Response (a Disease Activity Composite Index)

The BICLA response was defined as BILAG-2004 improvement (all screening visit BILAG A improving to B/C/D, all screening visit BILAG B to C/D, and less than or equal to (\<=1) new BILAG B and no new BILAG A); no deterioration in SLEDAI total score; PGA increase by less than (\<) 0 percentage (%) (defined as less then (\<)0.3 point increase for the statistical analyses) and no non-permitted medication/treatment. Baseline was defined as core study screening visit.

Time frame:
Baseline: Core study Screening; LTE Day 1, Week 24, Week 48, Week 72 and Week 96
Reported as:
Count of participants · Participants
Number of Participants Who Achieved BILAG-based Combined Lupus Assessment (BICLA) Response (a Disease Activity Composite Index)
ParticipantsPlacebo/Atacicept 150 mgAtacicept 75 mgAtacicept 150 mg
LTE Day 1434350
LTE Week 24404553
LTE Week 48353443
LTE Week 72161721
LTE Week 96479
SecondaryPercent Change From Baseline in Prednisone-equivalent Corticosteroid Dose
Time frame:
Baseline: Screening Visit (Core Study); LTE Day 1, Week 24, Week 48, Week 72 and Week 96
Reported as:
Mean · Percent change
Percent Change From Baseline in Prednisone-equivalent Corticosteroid Dose
Percent changePlacebo/Atacicept 150 mgAtacicept 75 mgAtacicept 150 mg
Percent Change at LTE Day 1-11.04 ± 31.139-5.25 ± 55.697-11.54 ± 26.117
Percent Change at LTE Week 24-11.89 ± 41.411-4.79 ± 59.371-1.21 ± 94.677
Percent Change at LTE Week 48-9.19 ± 54.364-6.01 ± 45.605-17.97 ± 37.040
Percent Change at LTE Week 72-19.32 ± 38.157-8.69 ± 28.112-22.34 ± 36.058
Percent Change at LTE Week 96-36.67 ± 58.146-12.40 ± 73.793-28.57 ± 43.080
SecondaryChange From Baseline in the Short-Form (SF-36) Health Survey Physical Component Score and Mental Component Score

The 36-Item Short-Form Health Survey (SF-36) is a standardized survey evaluating 8 aspects of functional health and well-being. These eight subscales were summarized as relating to either physical health or mental health. Physical component summary (PCS) is based primarily on physical functioning, role-physical, bodily pain, and general health scales and mental component summary (MCS) encompasses vitality, social functioning, role-emotional, and mental health scales. Score from mental health, role emotional, social functioning, and vitality domains were averaged to calculate MCS. Total score range for MCS was 0-100 (100=highest level of mental functioning). Score from physical function, role physical, bodily pain, and general health domains were averaged to calculate PCS. Total score range for PCS was 0-100 (100=highest level of physical functioning).

Time frame:
Baseline (Core Study Day 1); LTE Day 1, Week 24, Week 48, Week 72 and Week 96
Reported as:
Mean · Units on a scale
Change From Baseline in the Short-Form (SF-36) Health Survey Physical Component Score and Mental Component Score
Units on a scalePlacebo/Atacicept 150 mgAtacicept 75 mgAtacicept 150 mg
PCS: Baseline (Core Study Day 1)37.7 ± 9.2037.8 ± 10.5638.8 ± 9.27
PCS: Change at LTE Day 14.8 ± 10.004.8 ± 8.304.0 ± 7.46
PCS: Change at LTE Week 245.3 ± 8.625.1 ± 8.785.9 ± 7.74
PCS: Change at LTE Week 486.4 ± 9.566.2 ± 9.674.6 ± 8.23
PCS: Change at LTE Week 725.8 ± 8.613.4 ± 7.376.7 ± 5.33
PCS: Change at LTE Week 9613.0 ± 9.513.1 ± 9.298.9 ± 6.08
MCS: Baseline (Core Study Day 1)41.3 ± 10.7043.3 ± 12.0943.2 ± 10.81
MCS: Change at LTE Day 12.1 ± 11.382.2 ± 12.621.9 ± 9.30
MCS: Change at LTE Week 244.4 ± 10.433.0 ± 11.752.0 ± 10.26
MCS: Change at LTE Week 483.3 ± 11.722.8 ± 13.193.5 ± 11.39
MCS Change at LTE Week 723.8 ± 10.961.1 ± 11.741.5 ± 13.64
MCS: Change at LTE Week 9610.3 ± 15.860.6 ± 9.033.2 ± 12.20
SecondaryChange From Baseline in Lupus Quality of Life (LupusQoL) Questionnaire Score

The LupusQoL was a lupus-specific health related QoL (HRQoL) questionnaire consisting of 34 items grouped in 8 domains: physical health, pain, planning, intimate relationships, burden to others, emotional health, body image, and fatigue. Participants indicate their responses on a 5-point Likert response format, where 4 = never, 3 = occasionally, 2 = a good bit of the time, 1 = most of the time, and 0 = all of the time. Summary scores can be calculated for all 8 domains. A LupusQoL score for each domain was reported on a 0 to 100 scale, with greater values indicating better HRQoL. Baseline was defined as Day 1 of core study.

Time frame:
Baseline (Core Study Day 1); LTE Day 1, Week 24, Week 48, Week 72, and Week 96
Reported as:
Mean · Units on a scale
Change From Baseline in Lupus Quality of Life (LupusQoL) Questionnaire Score
Units on a scalePlacebo/Atacicept 150 mgAtacicept 75 mgAtacicept 150 mg
Physical Health: Baseline (Core study Day 1)60.2 ± 23.0862.0 ± 27.1761.3 ± 27.87
Physical Health: Change at LTE Day 18.8 ± 21.867.5 ± 17.378.2 ± 16.40
Physical Health: Change at LTE Week 2410.4 ± 21.2710.8 ± 18.8610.9 ± 18.46
Physical Health: Change at LTE Week 489.3 ± 22.2311.2 ± 24.8012.8 ± 20.30
Physical Health: Change at LTE Week 728.0 ± 19.425.9 ± 17.6111.9 ± 20.02
Physical Health: Change at LTE Week 9625.0 ± 21.4612.9 ± 17.9714.4 ± 10.33
Pain: Baseline (Core study Day 1)58.7 ± 26.7761.2 ± 30.2757.7 ± 31.52
Pain: Change at LTE Day 111.8 ± 24.8611.0 ± 23.9313.4 ± 21.78
Pain: Change at LTE Week 2414.4 ± 26.2111.9 ± 23.3816.4 ± 24.10
Pain: Change at LTE Week 4812.8 ± 27.7614.0 ± 29.6417.3 ± 24.67
Pain: Change at LTE Week 7216.7 ± 26.7310.3 ± 18.9117.2 ± 26.63
Pain: Change at LTE Week 9641.7 ± 30.2111.9 ± 23.7317.9 ± 23.78
Planning: Baseline (Core study Day 1)65.6 ± 27.5268.3 ± 30.8164.6 ± 33.26
Planning: Change at LTE Day 18.4 ± 25.601.5 ± 22.797.5 ± 23.08
Planning: Change at LTE Week 2411.2 ± 27.347.0 ± 24.168.4 ± 25.29
Planning: Change at LTE Week 4814.5 ± 29.276.5 ± 26.8810.9 ± 26.16
Planning: Change at LTE Week 7210.3 ± 22.230.0 ± 28.3715.5 ± 30.52
Planning: Change at LTE Week 9619.8 ± 36.983.0 ± 24.5921.8 ± 26.03
Intimate Relationship: Baseline (Core study Day 1)67.2 ± 30.9960.6 ± 34.1762.1 ± 31.62
Intimate Relationship: Change at LTE Day 13.9 ± 26.950.2 ± 27.77-1.6 ± 23.94
Intimate Relationship: Change at LTE Week 243.6 ± 26.297.1 ± 24.506.3 ± 25.67
Intimate Relationship: Change at LTE Week 482.3 ± 29.195.7 ± 33.028.4 ± 30.58
Intimate Relationship: Change at LTE Week 72-6.3 ± 20.67-2.8 ± 29.895.2 ± 32.95
Intimate Relationship: Change at LTE Week 9612.5 ± 15.312.9 ± 16.26-14.3 ± 39.81
Burden to Others: Baseline (Core study Day 1)49.0 ± 31.2248.5 ± 32.3447.3 ± 32.97
Burden to Others: Change at LTE Day 113.4 ± 26.3114.7 ± 25.8312.5 ± 25.36
Burden to Others: Change at LTE Week 2413.1 ± 26.0816.8 ± 27.3515.7 ± 27.73
Burden to Others: Change at LTE Week 4813.4 ± 25.6918.3 ± 30.3617.9 ± 28.73
Burden to Others: Change at Week 7212.1 ± 21.8914.4 ± 32.2322.1 ± 31.68
Burden to Others: Change at LTE Week 9617.7 ± 32.5620.2 ± 33.2930.1 ± 37.51
Emotional Health: Baseline (Core study Day 1)64.1 ± 23.4368.3 ± 25.8667.6 ± 27.10
Emotional Health: Change at LTE Day 17.9 ± 19.736.0 ± 20.087.0 ± 21.21
Emotional Health: Change at LTE Week 2411.2 ± 20.676.7 ± 21.877.9 ± 20.68
Emotional Health: Change at LTE Week 4814.2 ± 21.919.3 ± 25.668.0 ± 21.73
Emotional Health: Change at LTE Week 7210.1 ± 20.493.2 ± 17.5011.5 ± 26.30
Emotional Health: Change at LTE Week 9622.4 ± 26.166.8 ± 12.4016.3 ± 22.08
Body Image: Baseline (Core study Day 1)63.8 ± 27.8261.9 ± 31.4564.4 ± 30.51
Body Image: Change at LTE Day 112.9 ± 24.476.2 ± 20.694.7 ± 25.29
Body Image: Change at LTE Week 2413.2 ± 25.949.1 ± 22.334.5 ± 29.34
Body Image: Change at LTE Week 4811.6 ± 25.3914.9 ± 25.107.5 ± 28.45
Body Image: Change at Week 7211.0 ± 19.158.5 ± 16.3413.8 ± 29.79
Body Image: Change at LTE Week 9627.1 ± 32.7913.4 ± 21.8710.5 ± 38.19
Fatigue: Baseline (Core study Day 1)53.4 ± 26.8355.6 ± 27.8256.8 ± 29.00
Fatigue: Change at LTE Day 19.3 ± 21.475.9 ± 21.057.0 ± 20.93
Fatigue: Change at LTE Week 2410.6 ± 23.777.1 ± 20.898.2 ± 21.96
Fatigue: Change at LTE Week 487.1 ± 23.2811.9 ± 22.0510.8 ± 20.05
Fatigue: Change at LTE Week 726.7 ± 25.982.7 ± 20.5514.7 ± 30.63
Fatigue: Change at LTE Week 9621.1 ± 33.732.7 ± 23.0920.2 ± 21.06
SecondaryNumber of Participants With Patient Global Impression of Change (PGIC)

The PGIC is self-rated scale that asks the participant to describe the change in activity limitations, symptoms, emotions, and overall Quality of life (QoL) related to the participant's painful condition on the following scale: 1 (very much improved), 2 (much improved), 3 (minimally improved), 4 (no change), 5 (minimally worse), 6 (much worse) and 7 (very much worse). Number of participants in the PGIC categories of very much improved (1) and much improved (2) are reported.

Time frame:
Baseline (Core Study Day 1); LTE Day 1, Week 24, Week 48, Week 72 and Week 96
Reported as:
Count of participants · Participants
Number of Participants With Patient Global Impression of Change (PGIC)
ParticipantsPlacebo/Atacicept 150 mgAtacicept 75 mgAtacicept 150 mg
LTE Day 1: Very much improved131925
LTE Day 1: Much improved293327
LTE Week 24: Very much improved182222
LTE Week 24: Much improved352940
LTE Week 48: Very much improved162024
LTE Week 48: Much improved262430
LTE Week 72: Very much improved71010
LTE Week 72: Much improved131313
LTE Week 96: Very much improved427
LTE Week 96: Much improved475
SecondaryChange From Baseline in EuroQoL 5 Dimension Instrument (EQ-5D) Score

EQ-5D questionnaire comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression measured on 3 levels; 1=no problem, 2=moderate problems, 3=extreme problems. This part, called the EQ-5D descriptive system, provides a 5-dimensional description of health status. 5 dimensional 3-level system was converted into single index utility score. Possible values for single index utility score ranged from -0.594 (severe problems in all dimensions) to 1.0 (no problem in all dimensions) on scale where 1 represented best possible health state. Baseline was defined as Day 1 of Core study.

Time frame:
Baseline: Day 1 (Core Study), LTE Day 1, Week 24, Week 48, Week 72 and Week 96
Reported as:
Mean · Units on a scale
Change From Baseline in EuroQoL 5 Dimension Instrument (EQ-5D) Score
Units on a scalePlacebo/Atacicept 150 mgAtacicept 75 mgAtacicept 150 mg
Baseline (Core Study Day 1)0.736 ± 0.17070.775 ± 0.17540.751 ± 0.2388
Change at LTE Day 10.038 ± 0.17640.042 ± 0.17590.070 ± 0.1912
Change at LTE Week 240.078 ± 0.16510.024 ± 0.22070.072 ± 0.1933
Change at LTE Week 480.065 ± 0.20500.045 ± 0.23930.076 ± 0.2414
Change at LTE Week 720.045 ± 0.15310.000 ± 0.21260.087 ± 0.2609
Change at LTE Week 960.138 ± 0.1257-0.015 ± 0.17670.132 ± 0.1927
SecondaryChange From Baseline in EQ-5D Visual Analogue Scale (VAS) Scores

EQ-5D is a participant rated questionnaire to assess health-related QoL in terms of a single index value. The VAS component rates current health state on a scale from 0 millimeters (mm) (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state. Baseline defined as Day 1 of core study.

Time frame:
Baseline: Day 1 (Core Study), LTE Day 1, Week 24, Week 48, Week 72 and Week 96
Reported as:
Mean · mm
Change From Baseline in EQ-5D Visual Analogue Scale (VAS) Scores
mmPlacebo/Atacicept 150 mgAtacicept 75 mgAtacicept 150 mg
Baseline (Core Study Day 1)61 ± 18.865 ± 21.465 ± 22.2
Change at LTE Day 19 ± 16.011 ± 21.58 ± 18.1
Change at LTE Week 2413 ± 19.712 ± 21.411 ± 18.4
Change at LTE Week 4815 ± 18.414 ± 23.99 ± 19.6
Change at LTE Week 7212 ± 18.912 ± 19.610 ± 18.1
Change at LTE Week 9619 ± 17.612 ± 20.910 ± 21.6
SecondaryChange From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score

The FACIT-Fatigue score was calculated according to a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function. It uses a 5-point Likert-type scale (0 = not at all; 1 = a little bit; 2 = somewhat; 3 = quite a bit; 4 = very much). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse possible score) to 52 (best score). A higher score reflected an improvement in the participant's health status.

Time frame:
Baseline: Day 1 (Core study); LTE Day 1, Week 24, Week 48, Week 72 and Week 96
Reported as:
Mean · Units on a scale
Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score
Units on a scalePlacebo/Atacicept 150 mgAtacicept 75 mgAtacicept 150 mg
Baseline; Day 1 (Core Study)29 ± 10.132 ± 13.131 ± 13.1
Change at LTE Day 14 ± 9.54 ± 10.24 ± 9.8
Change at LTE Week 245 ± 10.13 ± 10.94 ± 9.9
Change at LTE Week 485 ± 11.24 ± 12.35 ± 9.9
Change at LTE Week 724 ± 11.32 ± 10.26 ± 10.2
Change at LTE Week 9613 ± 15.53 ± 8.49 ± 9.2
SecondaryNumber of Participants With at Least One Adverse Event

An Adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease associated with the use of study drug, whether or not considered related to the study drug or worsening of pre-existing medical condition, whether or not related to study drug. Treatment-Emergent adverse events (TEAEs) are defined as events with an onset date on or after the date of first dose of study treatment in the core study and ongoing at LTE study entry, or occurring during LTE study.

Time frame:
Baseline (Day 1 of Core study) up to maximum duration of 167.7 weeks
Reported as:
Count of participants · Participants
Number of Participants With at Least One Adverse Event
ParticipantsPlacebo/Atacicept 150 mgAtacicept 75 mgAtacicept 150 mg
Number of Participants With at Least One Adverse Event686776
SecondaryNumber of Participants With Columbia-Suicide Severity Rating Scale (C-SSRS) Score

The C-SSRS assesses the suicidal behavior and suicidal ideation in participants. Occurrence of suicidal behavior after study entry is defined as having answered "yes" to a least 1 of the 4 suicidal behavior subcategories (actual attempt, interrupted attempt, aborted attempt, and preparatory acts or behavior). Occurrence of suicidal ideation is defined as having answered "yes" to at least 1 of the suicidal ideation sub-categories (1) wish to be dead, (2) nonspecific active suicidal thoughts, (3) active suicidal ideation with any methods (no plan) without intent to act, (4) active suicidal ideation with some intent to act (without specific plan), and (5) active suicidal ideation with specific plan and intent).

Time frame:
LTE Day 1, Week 24, Week 48, Week 72 and Week 98
Reported as:
Count of participants · Participants
Number of Participants With Columbia-Suicide Severity Rating Scale (C-SSRS) Score
ParticipantsPlacebo/Atacicept 150 mgAtacicept 75 mgAtacicept 150 mg
Occurrence of Suicidal Behavior at LTE Day 1000
Occurrence of Suicidal Behavior at LTE Week 24000
Occurrence of Suicidal Behavior at LTE Week 48000
Occurrence of Suicidal Behavior at LTE Week 72000
Occurrence of Suicidal Behavior at LTE Week 96000
Occurrence of Suicidal Ideation at LTE Day 1000
Occurrence of Suicidal Ideation at LTE Week 24000
Occurrence of Suicidal Ideation at LTE Week 48000
Occurrence of Suicidal Ideation at LTE Week 72101
Occurrence of Suicidal Ideation at LTE Week 96010

Adverse events

Collected over Baseline up to maximum duration of 167.7 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo/Atacicept 150 mg0/83 (0%)19/83 (22.9%)65/83 (78.3%)
Atacicept 75 mg0/82 (0%)13/82 (15.9%)65/82 (79.3%)
Atacicept 150 mg2/88 (2.3%)11/88 (12.5%)75/88 (85.2%)
Most frequent serious events
Showing 10 of 60
Most frequent serious events
EventPlacebo/Atacicept 150 mgAtacicept 75 mgAtacicept 150 mg
PneumoniaInfections and infestations2/832/821/88
Systemic lupus erythematosusMusculoskeletal and connective tissue disorders0/832/821/88
Herpes zosterInfections and infestations2/830/820/88
Pleural effusionRespiratory, thoracic and mediastinal disorders0/830/822/88
Meniere's diseaseEar and labyrinth disorders0/831/820/88
GastritisGastrointestinal disorders0/831/821/88
Soft tissue infectionInfections and infestations0/831/820/88
Animal biteInjury, poisoning and procedural complications0/831/820/88
Radius fractureInjury, poisoning and procedural complications0/831/820/88
HypocalcaemiaMetabolism and nutrition disorders0/831/821/88
Most frequent other events
Showing 10 of 13
Most frequent other events
EventPlacebo/Atacicept 150 mgAtacicept 75 mgAtacicept 150 mg
Injection site reactionGeneral disorders23/8314/8222/88
Urinary tract infectionInfections and infestations18/8314/8217/88
Upper respiratory tract infectionInfections and infestations7/8311/8215/88
Injection site painGeneral disorders11/834/8214/88
HeadacheNervous system disorders11/833/8210/88
BronchitisInfections and infestations7/8310/822/88
NasopharyngitisInfections and infestations8/838/825/88
SinusitisInfections and infestations3/837/825/88
Back painMusculoskeletal and connective tissue disorders3/837/824/88
PharyngitisInfections and infestations3/836/826/88

Baseline characteristics

Modified intent-to-treat (mITT) analysis set: defined as all enrolled participants in the LTE study. Efficacy analyses were performed on the mITT analysis set according to randomized treatment.

Age, Continuous
Age, Continuous(Years)Placebo/Atacicept 150 mgAtacicept 75 mgAtacicept 150 mgTotal
Mean41 ± 13.037 ± 10.738 ± 11.539 ± 11.8
Sex: Female, Male
Sex: Female, Male(Participants)Placebo/Atacicept 150 mgAtacicept 75 mgAtacicept 150 mgTotal
Female747582231
Male97622
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo/Atacicept 150 mgAtacicept 75 mgAtacicept 150 mgTotal
Hispanic or Latino484340131
Not Hispanic or Latino353948122
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo/Atacicept 150 mgAtacicept 75 mgAtacicept 150 mgTotal
American Indian or Alaska Native43310
Asian7131333
Native Hawaiian or Other Pacific Islander1001
Black or African American33713
White645855177
More than one race0000
Unknown or Not Reported451019
08

Study locations

84 sites
  • Pinnacle Research Group LLC
    Anniston, Alabama 36207, United States
  • University of Alabama at Birmingham - (UAB)
    Birmingham, Alabama 35294, United States
  • Wallace Rheumatic Study Center
    Beverly Hills, California 90211, United States
  • Southern California Permenent Medical Group
    Fontana, California 92335, United States
  • East Bay Rheumatology Medical Group, Inc.
    San Leandro, California 94578, United States
  • Clinical Research of West Florida - Corporate
    Clearwater, Florida 33765, United States
  • Clinical Research of West Florida, Inc.
    Tampa, Florida 33603, United States
  • McIlwain Medical Group, PA
    Tampa, Florida 33613, United States
  • AA MRC LLC Ahmed Arif Medical Research Center
    Grand Blanc, Michigan 48439, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Washington University
    Saint Louis, Missouri 63110, United States
  • Clayton Medical Associates, P.C.
    Saint Louis, Missouri 63117, United States
  • Rutgers New Jersey Medical School
    Newark, New Jersey 07103, United States
  • The Feinstein Institute for Medical Research
    Manhasset, New York 11031, United States
  • Hospital for Special Surgery
    New York, New York 10021, United States
  • DJL Clinical Research, PLLC
    Charlotte, North Carolina 28210, United States
  • MetroHealth System
    Cleveland, Ohio 44109, United States
  • Arthritis & Rheumatology Center of Oklahoma
    Oklahoma City, Oklahoma 73103, United States
  • OMRF
    Oklahoma City, Oklahoma 73104, United States
  • Clinical Research Center of Reading LLC
    Wyomissing, Pennsylvania 19610, United States
  • Medical University of South Carolina (MUSC)
    Charleston, South Carolina 29425, United States
  • Austin Regional Clinic, P.A.
    Austin, Texas 78731, United States
  • Little River Arthritis & Osteoporosis Clinic
    Waco, Texas 76708, United States
  • Instituto CAICI
    Rosario, Santa Fe S2000PBJ, Argentina
  • Centro Medico Privado de Reumatologia
    San Miguel de Tucuman, Tucuman T4000AXL, Argentina
  • Investigaciones Clinicas Tucuman
    San Miguel de Tucuman, Tucuman T4000ICL, Argentina
  • Centro Integral de Reumatologia
    San Miguel de Tucumán, Tucuman T4000DVB, Argentina
  • Organizacion Medica de Investigacion (OMI)
    Ciudad Autonoma Buenos Aires, C1015ABO, Argentina
  • APRILLUS
    Ciudad Autonoma Buenos aires, C1046AAQ, Argentina
  • Atencion Integral en Reumatologia (AIR)
    Ciudad Autonoma Buenos Aires, C1426AAL, Argentina
  • Hospital Privado Centro Medico de Cordoba
    Cordoba, X5016KEH, Argentina
  • Cordis S.A.
    Salta, A4400ANW, Argentina
  • Centro Polivalente de Asistencia e Inv. Clinica CER
    San Juan, 5400, Argentina
  • Centro de Pesquisas em Diabetes Ltda.
    Porto Alegre, Rio Grande Do Sul 90035-170, Brazil
  • MHAT "Eurohospital" - Plovdiv, OOD
    Plovdiv, 4002, Bulgaria
  • Medical Center "Teodora", EOOD
    Ruse, 7000, Bulgaria
  • MHAT - Ruse, AD
    Ruse, 7002, Bulgaria
  • UMHAT "Sv. Ivan Rilski", EAD
    Sofia, 1431, Bulgaria
  • DCC "Sveta Anna", EOOD
    Sofia, 1750, Bulgaria
  • Medical Center "Nov Rehabilitatsionen Tsentar", EOOD
    Stara Zagora, 6000, Bulgaria
  • MHAT-Targovishte, AD
    Targovishte, 7700, Bulgaria
  • Corporacion de Beneficencia Osorno
    Osorno, 5290000, Chile
  • Quantum Research Santiago
    Puerto Varas, 5550170, Chile
  • Centro Medico Prosalud
    Santiago, 7500000, Chile
  • Biomedica
    Santiago, 7500710, Chile
  • Centro de Estudios Reumatologicos
    Santiago, 7501126, Chile
  • CINVEC - Centro de Investigacion Clinica V Region
    Viña del Mar, Chile
  • Revmatologicky Ustav
    Praha 2, 128 50, Czechia
  • Revmatologicka ambulance
    Uherske Hradiste, 686 01, Czechia
  • Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz
    Mainz, Rheinland Pfalz 55131, Germany
  • Charite Universitaetsmedizin Berlin - Campus Charite Mitte
    Berlin, 13353, Germany
  • Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico
    Milano, 20122, Italy
  • Seoul National University Hospital
    Seoul, Gyeonggi-do 110744, Korea, Republic of
  • Ajou University Hospital
    Suwon-si, Gyeonggi-do 16499, Korea, Republic of
  • Konkuk University Medical Center
    Seoul, 05030, Korea, Republic of
  • Hospital Universitario de Saltillo "Dr. Gonzalo Valdés Valdés"
    Saltillo, Coahuila 25000, Mexico
  • Clinstile, S.A. de C.V.
    Mexico, Distrito Federal 06700, Mexico
  • Morales Vargas Centro de Investigacion, S.C.
    Leon, Guanajuato 37000, Mexico
  • Icle S.C.
    Guadalajara, Jalisco 44600, Mexico
  • Unidad de Investigacion en Enfermedades Cronico Degenerativas SC
    Guadalajara, Jalisco 44620, Mexico
  • Clinica de Enfermedades Cronicas y de Procedimientos Especiales, S.C.
    Morelia, Michoacán 58249, Mexico
  • Accelerium S. de R.L. de C.V.
    Monterrey, Nuevo León 64000, Mexico
  • Centro Multidisciplinario para el desarrollo Especializado de la Investigacion Clinica en Yucatan
    Merida, Yucatán 97130, Mexico
  • Investigacion y Biomedicina de Chihuahua, S.C.
    Chihuahua, 31000, Mexico
  • Hogar Clínica San Juan de Dios - Arequipa
    Arequipa, 00000, Peru
  • Clinica Medica Cayetano Heredia
    Lima, Lima 31, Peru
  • Invest Clinicas Sac Inst de Ginecologia y Reproduccion
    Lima, Lima 33, Peru
  • Angeles University Foundation Medical Center
    Angeles City, Pampanga, 2009, Philippines
  • Mary Mediatrix Medical Center
    Batangas, 4127, Philippines
  • Davao Doctors Hospital
    Davao, 8000, Philippines
  • Iloilo Doctors Hospital
    Iloilo, 5000, Philippines
  • Szpital Uniwersytecki nr 2 im.dr J. Biziela
    Bydgoszcz, 85-168, Poland
  • FSBEI HE " First Moscow State Medical University n.a. I.M. Sechenov" of the MoH of the RF
    Moscow, 119992, Russian Federation
  • SBIH of Republic Kareliya "Republican Hospital n.a. V.A. Baranov"
    Petrozavodsk, 185019, Russian Federation
  • SPb SBIH "Clinical Rheumatological Hospital # 25"
    Saint-Petersburg, 190068, Russian Federation
  • SIH "Saratov City Clinical Hospital # 12"
    Saratov, 410039, Russian Federation
  • SBIH of Vladimir region "Regional Clinical Hospital"
    Vladimir, 600023, Russian Federation
  • SBHI of Yaroslavl Region "Clinical Hospital # 8"
    Yaroslavl, 150003, Russian Federation
  • Naidoo, A
    Durban, KwaZulu-Natal 4319, South Africa
  • Winelands Medical Research Centre
    Stellenbosch, Western Cape 7600, South Africa
  • Hospital Clinico Universitario de Valladolid
    Valladolid, 47005, Spain
  • Queen's Hospital
    Romford, Essex RM7 0AG, United Kingdom
  • University College London Hospitals
    London, Greater London NW1 2PG, United Kingdom
  • Guy's Hospital
    London, Greater London SE1 7EH, United Kingdom
09

References and documents

Publications

  • Wallace DJ, Isenberg DA, Morand EF, Vazquez-Mateo C, Kao AH, Aydemir A, Pudota K, Ona V, Aranow C, Merrill JT. Safety and clinical activity of atacicept in the long-term extension of the phase 2b ADDRESS II study in systemic lupus erythematosus. Rheumatology (Oxford). 2021 Nov 3;60(11):5379-5389. doi: 10.1093/rheumatology/keab115. PubMed 33547784 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2014 to primary completion in Apr 2016, 20 months.

Results were first posted in Mar 2019, 2 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2014
First posted
Feb 25, 2014
StartActual
Jul 29, 2014
Primary completionActual
Apr 5, 2016
CompletionActual
Feb 9, 2018
Results first posted
Mar 21, 2019
Last update
Mar 21, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 21, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02070978
Lead sponsor
EMD Serono
Responsible party
Sponsor
First posted
Feb 25, 2014
Start date
Jul 29, 2014
Primary completion
Apr 5, 2016
Completion
Feb 9, 2018
Results posted
Mar 21, 2019
Last update
Mar 21, 2019

Study contacts

Medical Responsible
study director · EMD Serono, Inc., Rockland MA, a subsidiary of Merck KGaA, Darmstadt, Germany

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TACI receptor-IgG Fc fragment fusion protein

Start the discussion